Ticagrelor exporter good producer 274693-27-5 global CAS NO.274693-27-5

Ticagrelor Manufacturers Fast delivery CAS 274693-27-5 Hot sale

Tikagre is a new antiplatelet coagulation drug developed by AstraZeneca in the United States and is the world's first reversible binding oral P2Y12 adenosine disphosphate receptor antagonist, which is reversible The subtype P2Y12, which acts sexually on the smooth muscle cells (VSMC) of the blood vessels, does not require metabolic activation and has a significant inhibitory effect on platelet aggregation caused by adenosine diphosphate (ADP). And oral use after rapid effect, can effectively improve the symptoms of acute coronary heart disease patients. Unlike anticoagulants, tikagre is a reversible inhibitor of P2Y12 receptors, so it is especially suitable for patients who need to undergo anticoagulant therapy before surgery.

Our advantages:

1. All inquiries will be replied within 12 hours.

2. Dedication to quality, supply & service.

3. Strictly on selecting raw materials.

3. OEM/ODM Available.

4. Reasonable & competitive price, fast lead time.

5. Sample is available for your evaluation & Formulation development.

6. Faster delivery:Sample order in stock and 3-7 days for bulk production.

7. We have strong cooperation with DHL, TNT, UPS, FEDEX, EMS. Or you also can choose your own shipping forwarder.